The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial.
Patrizia Giannatempo
No relevant relationships to disclose
Nicola Nicolai
No relevant relationships to disclose
Elena Farè
No relevant relationships to disclose
Daniele Raggi
No relevant relationships to disclose
Luigi Piva
No relevant relationships to disclose
Davide Biasoni
No relevant relationships to disclose
Mario Catanzaro
No relevant relationships to disclose
Tullio Torelli
No relevant relationships to disclose
Silvia Stagni
No relevant relationships to disclose
Massimo Maffezzini
No relevant relationships to disclose
Alessandro Crestani
No relevant relationships to disclose
Elena Togliardi
No relevant relationships to disclose
Roberto Salvioni
No relevant relationships to disclose
Alessandro M. Gianni
No relevant relationships to disclose
Andrea Necchi
No relevant relationships to disclose